OPtimisation of Antiviral Therapy in Immunocompromised COVID-19 Patients

Summary

The overall purpose of the trial is to evaluate the efficacy and safety of possible combination antiviral therapy direct antiviral agents (remdesivir + nirmatrelvir/r) versus the reference monotherapy (nirmatrelvir/r alone) and to assess the efficacy and safety of increasing the nirmatrelvir/r course from 5- to 10 days in immunocompromised patients diagnosed with asymptomatic or mild to moderate Coronavirus Disease 2019 (COVID-19).

Timeline

Start

2023-04-27

Primary completion

2026-04-10

Completion

2026-06-30

Drugs

Indications